Australia markets closed

Immuron Limited (IMC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1150+0.0050 (+4.55%)
At close: 04:10PM AEDT
Full screen
Previous close0.1100
Open0.1100
Bid0.1100 x 3350000
Ask0.1150 x 10984500
Day's range0.1100 - 0.1150
52-week range0.0650 - 0.1700
Volume258,892
Avg. volume1,275,201
Market cap26.197M
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date28 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • GlobeNewswire

    Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

    Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secon

  • GlobeNewswire

    Immuron achieves record Travelan® sales

    Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6 millionCanadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-co